Continuous-flow system went from synthesis to dosage forms in hours.
Drug manufacturers typically produce drugs in batches in large factories. But a new trend is developing in the pharmaceutical industry to reduce infrastructure costs by using small continuous-flow systems to make drug doses on demand.
Let’s show them we appreciate! smile
Removing senescent cells could help reduce age-related diseases and improve health. You have the power to help shape the future of medicine by supporting the CellAge campaign at lifespan.io check it out on the link below:
https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/
For just $25 your name will be converted into cool DNA coding language and placed in the special CellAge time capsule for a future generation to discover!
Your donation could help us to develop cures for age-related diseases, check out the CellAge project on Lifespan.io today.
https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/
Philadelphia, PA, USA / Moscow, Russia — Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, announced the commercial approval of naturally derived Bioquantine food ingredients in the Eurasian Customs Union (formerly known as the Customs Union of Belarus, Kazakhstan, and Russia). Moscow based, Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, collaborated with Bioquark Inc. on the regulatory approvals.
“We are very excited about this successful regulatory approval,” said Ira S. Pastor, CEO, Bioquark Inc. “The commercialization of Bioquantine food ingredients, including functional foods, drinks, and dietary supplements, represents another important step in our continued evolution as a company focused on a broad range of products and services in the regenerative healthcare space.”
Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.
The integration of a complex set of newer research disciplines, including interkingdom signaling, semiochemical communication, and evolutionary biology, as well as significant recent activity in the areas of the microbiome and virome, are highlighting a myriad of new ways that non-human bio-products can affect the human genome for positive transitions in health and wellness dynamics.
“Bioquark has spent several years studying the natural ability of many species to turn back biological time in order to maintain health, fitness, and survival,” said Dr. Sergei Paylian, Founder, CSO, and President, Bioquark Inc. “This Eurasian initiative is one more step in the path in allowing humans to recapture these capabilities to effectively counter our unfortunate progression into aging, disease and degeneration.”
About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.
Link to Press — http://www.prweb.com/releases/2017/01/prweb13955162.htm
In Brief
According to the World Health Organization, an estimated 285 million people are visually impaired, with 39 million living with blindness and the other 246 million having low vision.
In a world of modern technological advancements, visual impairment has been the subject of much medical research. Perhaps the most notable among these are those that use artificial intelligence (AI), specifically through machine learning. Google’s DeepMind has been working with the UK’s National Health Service to do ophthalmology research.
In Brief CRISPR has opened up limitless avenues for genetic modification. From disease prevention to invasive species control, Jennifer Kahn discusses the discover, application, and implications of gene drives.
Jennifer Kahn, a science journalist for the New York Times, recently did a TED Talk in which she discussed the discovery, application, and implications of a CRISPR gene drive used to make mosquitoes resistant to malaria and other diseases like chikungunya, and Zika.
Watch the talk in the video below, and learn how geneticists are achieving the (seemingly) impossible:
Despite efforts to raise public awareness about the disease, cases of melanoma, the most deadly form of skin cancer, have been on the rise in the United States for years. Now, scientists have discovered a new drug that can stop metastasis of the disease, that is, the development of melanoma cells elsewhere in the body — by as much as 90 percent.
The findings are courtesy of a new study published in the journal Molecular Cancer Therapeutics. For the study, researchers injected immuno-compromised mice with human melanoma cells and exposed them to a man-made, small-molecule drug that targets a gene’s ability to produce RNA molecules (one of the major building blocks of life) and certain proteins found in melanoma tumors. Those genes typically cause the disease to spread, but when they were exposed to the compound, up to 90 percent of the cells were prevented from metastasizing.
The potential drug, known as CCG-203971, is the same as the one the researchers have been studying as a potential treatment for scleroderma, a rare and often fatal autoimmune disease that causes the hardening of skin tissue, lungs, heart, kidneys, and other organs.
